‌

US Patent 11566041 Nucleotide prodrug compounds

Patent 11566041 was granted and assigned to Ligand Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Ligand Pharmaceuticals

Current Assignee

Ligand Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

115660410

Date of Patent

January 31, 2023

Patent Application Number

178358280

Date Filed

June 8, 2022

Patent Citations

‌

US Patent 10435429 5-fluorouridine monophosphate cyclic triester compounds

‌

US Patent 10000521 Substituted gemcitabine bicyclic amide analogs and treatment methods using same

‌

US Patent 10059733 Gemcitabine analogs

‌

US Patent 10899786 Nucleoside phosphate compound and preparation method and use thereof

Patent Citations Received

‌

US Patent 12110311 Cyclic deoxyribonucleotide compounds

Patent Primary Examiner

‌

Layla D Berry

Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11566041 Nucleotide prodrug compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API